32859260|t|Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report.
32859260|a|BACKGROUND: Rituximab is a well-established component of treatment regimens for B-cell non-Hodgkin lymphoma. Rituximab binds the CD20 antigen on the surface of B lymphocytes, causing an enhanced clearance of malignant and benign B cells. Thus, rituximab leads to depletion of normal B lymphocytes as well, which can cause substantial immunodeficiency. Ibrutinib inhibits the Bruton tyrosine kinase and thereby B-cell activity. It is used for the treatment of different B-lymphocyte malignancies, such as mantle cell lymphoma. Recently, the combination of both drugs has been tested in various clinical scenarios. CASE PRESENTATION: We present a case of disseminated enterovirus infection resulting from combined rituximab and ibrutinib maintenance treatment in a 57-year-old Caucasian patient. with mantle cell lymphoma. Initially presenting with myositis symptoms, further diagnostic investigation revealed myocarditis, enteritis, myeloencephalitis, and hepatitis. These organ manifestations led to potentially life-threatening complications such as rhabdomyolysis, delirium, and heart rhythm disturbances. After treatment with high-dose intravenous immunoglobulins, virus clearance was achieved and organ functions could be restored. CONCLUSIONS: This case emphasizes the risk of combined therapy with rituximab/ibrutinib for severe immune-related side effects with the necessity of continuous patient monitoring. High-dose intravenous therapy should be considered as treatment for severe enterovirus infection. In severe enterovirus infections, we recommend subtyping for the development of efficient preventive and therapeutic strategies.
32859260	30	51	enterovirus infection	Disease	MESH:D004769
32859260	68	77	rituximab	Chemical	MESH:D000069283
32859260	82	91	ibrutinib	Chemical	MESH:C551803
32859260	118	138	mantle cell lymphoma	Disease	MESH:D020522
32859260	167	176	Rituximab	Chemical	MESH:D000069283
32859260	235	262	B-cell non-Hodgkin lymphoma	Disease	MESH:D016393
32859260	264	273	Rituximab	Chemical	MESH:D000069283
32859260	284	288	CD20	Gene	54474
32859260	399	408	rituximab	Chemical	MESH:D000069283
32859260	489	505	immunodeficiency	Disease	MESH:D007153
32859260	507	516	Ibrutinib	Chemical	MESH:C551803
32859260	530	552	Bruton tyrosine kinase	Gene	695
32859260	624	649	B-lymphocyte malignancies	Disease	MESH:D015448
32859260	659	679	mantle cell lymphoma	Disease	MESH:D020522
32859260	821	842	enterovirus infection	Disease	MESH:D004769
32859260	867	876	rituximab	Chemical	MESH:D000069283
32859260	881	890	ibrutinib	Chemical	MESH:C551803
32859260	940	947	patient	Species	9606
32859260	954	974	mantle cell lymphoma	Disease	MESH:D020522
32859260	1002	1010	myositis	Disease	MESH:D009220
32859260	1063	1074	myocarditis	Disease	MESH:D009205
32859260	1076	1085	enteritis	Disease	MESH:D004751
32859260	1087	1104	myeloencephalitis	Disease	MESH:D004679
32859260	1110	1119	hepatitis	Disease	MESH:D056486
32859260	1206	1220	rhabdomyolysis	Disease	MESH:D012206
32859260	1222	1230	delirium	Disease	MESH:D003693
32859260	1236	1261	heart rhythm disturbances	Disease	MESH:D020178
32859260	1459	1468	rituximab	Chemical	MESH:D000069283
32859260	1469	1478	ibrutinib	Chemical	MESH:C551803
32859260	1551	1558	patient	Species	9606
32859260	1646	1667	enterovirus infection	Disease	MESH:D004769
32859260	1679	1701	enterovirus infections	Disease	MESH:D004769
32859260	Positive_Correlation	MESH:C551803	MESH:D004769
32859260	Positive_Correlation	MESH:C551803	MESH:D056486
32859260	Negative_Correlation	MESH:C551803	695
32859260	Negative_Correlation	MESH:C551803	MESH:D020522
32859260	Positive_Correlation	MESH:C551803	MESH:D020178
32859260	Bind	MESH:D000069283	54474
32859260	Negative_Correlation	MESH:D000069283	MESH:D020522
32859260	Positive_Correlation	MESH:D000069283	MESH:D004679
32859260	Negative_Correlation	MESH:C551803	MESH:D015448
32859260	Positive_Correlation	MESH:D000069283	MESH:D007153
32859260	Positive_Correlation	MESH:D000069283	MESH:D020178
32859260	Cotreatment	MESH:C551803	MESH:D000069283
32859260	Positive_Correlation	MESH:D000069283	MESH:D004769
32859260	Negative_Correlation	MESH:D000069283	MESH:D016393

